ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2028

Conditions

AML

Interventions

DRUG

MBG-453 + Azacitidine

Given intravenously (by vein)

Trial Locations (1)

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Australasian Leukaemia and Lymphoma Group

OTHER

lead

M.D. Anderson Cancer Center

OTHER